12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Deals

BioLineRx, Compugen deal

BioLineRx and Compugen partnered to develop products to treat diseases including acute and chronic inflammatory diseases, cardiac diseases, retinopathy and cancer. Compugen will grant BioLineRx exclusive, worldwide rights to products, primarily peptides, identified using Compugen's predictive drug discovery platforms. BioLineRx will be responsible for developing the products through Phase II testing....

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >